Invesaro

Stocks Health care JAZZ

NASDAQ · Health care

Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals plc brought in $4.6B of revenue over the twelve months to June 30, 2026, up 12.6% from a year earlier. Net income was $940.8M, a net margin of 20.4%. Operating cash flow minus capital spending left $1.3B of free cash flow in fiscal 2025. At June 30, 2026 it held $1.6B in cash against $4.4B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.

Price
$237.95
+0.71% on the day · September 25, 2026
52-week range $125.79 to $266.38
Market cap
$15.4B
Revenue (last 12 months)
$4.6B
+12.6% year on year
Net margin
20.4%

What Jazz Pharmaceuticals plc does

Jazz Pharmaceuticals plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JAZZ.

Revenue and profit by year

Revenue
FY18: $1.9B $1.9B FY18FY19: $2.2B $2.2B FY19FY20: $2.4B $2.4B FY20FY21: $3.1B $3.1B FY21FY22: $3.7B $3.7B FY22FY23: $3.8B $3.8B FY23FY24: $4.1B $4.1B FY24FY25: $4.3B $4.3B FY25
Net income
FY18: $447.1M $447.1M FY18FY19: $523.4M $523.4M FY19FY20: $238.6M $238.6M FY20FY21: -$329.7M -$329.7M FY21FY22: -$224.1M -$224.1M FY22FY23: $414.8M $414.8M FY23FY24: $560.1M $560.1M FY24FY25: -$356.1M -$356.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$4.3B-$430.2M-$356.1M-$5.84$1.3B
2024$4.1B$716.6M$560.1M$8.65$1.4B
2023$3.8B$578.6M$414.8M$6.10$1.1B
2022$3.7B-$65.5M-$224.1M-$3.58$1.2B
2021$3.1B$170.3M-$329.7M-$5.52$750.9M
2020$2.4B$378.1M$238.6M$4.22$884.6M

Latest SEC filings

What Jazz Pharmaceuticals plc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
  2. September 15, 2026
  3. August 31, 2026
  4. August 25, 2026
  5. August 10, 2026
  6. August 10, 2026
  7. August 6, 2026
  8. August 3, 2026
    Quarterly report 10-Q · period to June 30, 2026
  9. August 3, 2026
  10. July 24, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 14, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about JAZZ

What does Jazz Pharmaceuticals plc do?

Jazz Pharmaceuticals plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JAZZ.

Is Jazz Pharmaceuticals plc profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $940.8M on revenue of $4.6B, a net margin of 20.4%.

How much revenue does Jazz Pharmaceuticals plc make?

Over the twelve months to June 30, 2026 Jazz Pharmaceuticals plc reported revenue of $4.6B. That is 12.6% more than a year earlier.

When did Jazz Pharmaceuticals plc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 23, 2026.

Similar companies

Follow JAZZ

Get an email when Jazz Pharmaceuticals plc files with the SEC: results, executive changes, material agreements and annual reports.

Follow JAZZ: get an email when it files

Where the numbers come from

Financial figures are the values Jazz Pharmaceuticals plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.